Compare iShares MSCI Australia ETF (EWA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Sanofi SA — how do they compare? iShares MSCI Australia ETF trades at $28.27 (market cap $1.17B), while Sanofi SA trades at $40.2 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 81.4× iShares MSCI Australia ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Sanofi SA for 94 Days on average.
| EWA | SNY | |
|---|---|---|
Market Cap | $1.17B | $95.18B |
Volume | 2,121,231 | 2,995,646 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $52.34 |
52-Week Low | $24.95 | $39.51 |
Typical Hold Time | 63 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.23, down 1.12% amid broader Australian market weakness. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. Recent institutional activity includes Squarepoint Ops reducing its stake by 91.2% while other firms like Empowered Funds and Cetera Investment Advisers increased positions. The ETF serves as a commodity proxy, benefiting from Australia's export-driven economy.
The outlook remains cautious with technical weakness and mixed institutional sentiment. Upside potential exists if commodity demand drives Australian equities higher, but near-term risks include persistent inflation concerns and tight monetary policy. The Seeking Alpha buy rating targeting $34.83 suggests over 20% upside potential from current levels.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
